Beatrice Salimbeni-Taurelli

Milan, Italy

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 25 publications

Invasive lobular carcinoma: Strategies and perspectives from the lobular breast cancer research group.

Invasive lobular carcinoma: Strategies and perspectives from the lobular breast cancer research group.

Journal: Cancer treatment reviews
Published: July 02, 2025

Overcoming Resistance to CDK4/6 inhibitors in Hormone Receptor positive, HER2 negative breast cancer: Innovative Combinations and Emerging Strategies.

Overcoming Resistance to CDK4/6 inhibitors in Hormone Receptor positive, HER2 negative breast cancer: Innovative Combinations and Emerging Strategies.

Journal: Cancer treatment reviews
Published: April 24, 2025

Survival Following CDK4/6 Inhibitor Therapy for Hormone Receptor-Positive, ERBB2-Negative Metastatic Breast Cancer.

Survival Following CDK4/6 Inhibitor Therapy for Hormone Receptor-Positive, ERBB2-Negative Metastatic Breast Cancer.

Journal: JAMA network open
Published: February 21, 2025

Molecular tumour board in gastrointestinal cancers.

Molecular tumour board in gastrointestinal cancers.

Journal: ESMO open
Published: January 21, 2025

Advancing treatment choices: CDK4/6 inhibitor switching in HR+/HER2- metastatic breast cancer.

Advancing treatment choices: CDK4/6 inhibitor switching in HR+/HER2- metastatic breast cancer.

Journal: Breast (Edinburgh, Scotland)
Published: November 19, 2024

Metastasis-directed stereotactic radiotherapy and systemic treatment continuation for patients with oligoprogressive metastatic breast cancer.

Metastasis-directed stereotactic radiotherapy and systemic treatment continuation for patients with oligoprogressive metastatic breast cancer.

Journal: European journal of cancer (Oxford, England : 1990)
Published: November 11, 2024

Prognostic impact of tumor-infiltrating lymphocytes in HER2+ metastatic breast cancer receiving first-line treatment.

Prognostic impact of tumor-infiltrating lymphocytes in HER2+ metastatic breast cancer receiving first-line treatment.

Journal: NPJ breast cancer
Published: October 08, 2024

Genomic tests for risk stratification in patients with early human epidermal growth factor receptor 2-positive breast cancer.

Genomic tests for risk stratification in patients with early human epidermal growth factor receptor 2-positive breast cancer.

Journal: Current opinion in oncology
Published: September 09, 2024

Molecular tumor board in patients with metastatic breast cancer.

Molecular tumor board in patients with metastatic breast cancer.

Journal: Breast cancer research and treatment
Published: August 27, 2024

Author Correction: Clinical impact of drug-drug interactions on abemaciclib in the real-world experience of AB-ITALY study.

Author Correction: Clinical impact of drug-drug interactions on abemaciclib in the real-world experience of AB-ITALY study.

Journal: NPJ breast cancer
Published: August 02, 2024

Genomic and clinical landscape of metastatic hormone receptors-positive breast cancers carrying ESR1 alterations.

Genomic and clinical landscape of metastatic hormone receptors-positive breast cancers carrying ESR1 alterations.

Journal: ESMO open
Published: June 12, 2024

PARP Inhibitors for Breast Cancer Treatment: A Review.

PARP Inhibitors for Breast Cancer Treatment: A Review.

Journal: JAMA oncology
Published: March 21, 2024
Showing 1-12 of 25

Last Updated: 09/26/2026